Jaworski, J.P. and Cahn, P., 2018. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1. The Lancet HIV, 5(12), pp.e723-e731. https://doi.org/10.1016/S2352-3018(18)30174-7
Caskey, M., Klein, F. and Nussenzweig, M.C., 2019. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nature medicine, 25(4), pp.547-553. https://doi.org/10.1038/s41591-019-0412-8
Cunningham, C.K., McFarland, E.J., Morrison, R.L., Capparelli, E.V., Safrit, J.T., Mofenson, L.M., Mathieson, B., Valentine, M.E., Perlowski, C., Smith, B. and Hazra, R., 2020. Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants. The Journal of infectious diseases, 222(4), pp.628-636. https://doi.org/10.1093/infdis/jiz532
Mahomed, S., Garrett, N., Baxter, C., Abdool Karim, Q. and Abdool Karim, S.S., 2021. Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review. The Journal of Infectious Diseases, 223(3), pp.370-380. https://doi.org/10.1093/infdis/jiaa377
Van de Perre, P., Goga, A., Ngandu, N., Nagot, N., Moodley, D., King, R., Molès, J.P., Mosqueira, B., Chirinda, W., Scarlatti, G. and Tylleskär, T., 2021. Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions. The Lancet, 397(10281), pp.1316-1324. https://doi.org/10.1016/S0140-6736(21)00570-5
Goga, A.E., Van de Perre, P., Ngandu, N., Nagot, N., Abrams, E.J., Moodley, D., King, R., Molès, J.P., Chirinda, W., Scarlatti, G. and Tylleskär, T., 2021. Eliminating HIV transmission through breast milk from women taking antiretroviral drugs. bmj, 374. https://doi.org/10.1136/bmj.n1697
